Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
Acta Paediatr ; 104(8): e367-71, 2015 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-24673165

RESUMO

AIM: Many countries have guidelines recommending the use of oral zinc in acute dehydrating diarrhoea in children aged 2 months to 5 years of age, but no guidelines exist for older children. This study tested how effective existing recommendations are in children from 5 to 12 years of age. METHODS: Children hospitalised with acute dehydrating diarrhoea (n = 134) were randomised to receive 40 mg of oral zinc sulphate tablets or a placebo for 14 days. The primary outcome variable was the time taken for diarrhoea to stop. Secondary outcome variables included time taken for rehydration, duration of hospitalisation and recurrence of diarrhoea in the next 3 months. RESULTS: The median time for resolution of diarrhoea was 60 h in both groups. The zinc group was marginally better, but not statistically significant, for resolution (hazard ratio = 0.89, 95% CI 0.63-1.24), rehydration (hazard ratio = 0.93, 95% CI 0.66-1.32) and hospitalisation (hazard ratio = 0.94, 95% CI 0.67-1.34). The risk ratio of recurrence for zinc versus placebo (95% CI) was 0.65 [0.37-1.23] [p = 0.11]. CONCLUSION: Daily zinc supplements (40 mg for 14 days) in children aged 5-12 years with acute dehydrating diarrhoea did not shorten the duration of diarrhoea or reduce subsequent episodes. Further adequately sized, community-based trials are needed.


Assuntos
Desidratação/tratamento farmacológico , Diarreia/tratamento farmacológico , Zinco/administração & dosagem , Doença Aguda , Administração Oral , Criança , Pré-Escolar , Desidratação/etiologia , Desidratação/prevenção & controle , Diarreia/complicações , Diarreia/prevenção & controle , Suplementos Nutricionais , Método Duplo-Cego , Feminino , Humanos , Masculino , Admissão do Paciente , Falha de Tratamento
2.
Cleve Clin J Med ; 91(9 suppl 1): S19-S25, 2024 Sep 04.
Artigo em Inglês | MEDLINE | ID: mdl-39231601

RESUMO

Respiratory syncytial virus (RSV) is a threat to infants globally causing bronchiolitis and pneumonia. Despite decades of research, RSV outbreaks occur with only modest advancements in prevention or treatment. Vaccine development faced challenges because past attempts caused enhanced disease and treatment options demonstrated limited efficacy. Recent advancements, including maternal vaccines focusing on the prefusion form of the F glycoprotein are now showing significant benefits in preventing severe RSV-related illness in infants. Additionally, monoclonal antibodies offer prevention directly to newborns within 1 week of birth. These innovations have the potential to substantially change the impact of RSV.


Assuntos
Infecções por Vírus Respiratório Sincicial , Vacinas contra Vírus Sincicial Respiratório , Humanos , Infecções por Vírus Respiratório Sincicial/prevenção & controle , Infecções por Vírus Respiratório Sincicial/terapia , Lactente , Vírus Sincicial Respiratório Humano , Recém-Nascido , Criança , Anticorpos Monoclonais/uso terapêutico , Antivirais/uso terapêutico
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA